AHR and neoplasm: In 2011, the laboratory of M. Platten identified kynurenine (KYN), a metabolite from tryptophan, as an AhR ligand that contributes to (1) brain tumor proliferation and (2) abolishment of antitumor immune defenses acting on both tumor and immune cells [87].